Therapeutic Advances Propelled by Deciphering Tumor Biology and Immunology—Highlights of the 8th Heidelberg Myeloma Workshop

by Raphael Lutz, Mirco Friedrich, Marc Steffen Raab, Niels Weinhold, Hartmut Goldschmidt
Published 2021-08-01

Making clinical decisions based on measurable residual disease improves the outcome in multiple myeloma

by Joaquin Martinez-Lopez, Rafael Alonso, Sandy W. Wong, Rafael Rios, Nina Shah, Yanira Ruiz-Heredia, Jose Maria Sanchez-Pina, Ricardo Sanchez, Natasha Bahri, Irene Zamanillo, Maria Poza, Natalia Buenache, Cristina Encinas, Luis Juarez, Fatima Miras, Luis Collado, Santiago Barrio, Thomas Martin, Maria Teresa Cedena, Jeffrey Wolf
Published 2021-08-01

Measurable Residual Disease in Acute Myeloid Leukemia Using Flow Cytometry: A Review of Where We Are and Where We Are Going

by Caroline Dix, Tsun-Ho Lo, Georgina Clark, Edward Abadir
Published 2020-06-01

Prognostic and therapeutic implications of measurable residual disease in acute myeloid leukemia

by Marisa J. L. Aitken, Farhad Ravandi, Keyur P. Patel, Nicholas J. Short
Published 2021-09-01

B-Cell Regeneration Profile and Minimal Residual Disease Status in Bone Marrow of Treated Multiple Myeloma Patients

by Robéria Mendonça de Pontes, Juan Flores-Montero, Luzalba Sanoja-Flores, Noemi Puig, Roberto J. Pessoa de Magalhães, Alba Corral-Mateos, Anna Beatriz Salgado, Omar García-Sánchez, José Pérez-Morán, Maria-Victoria Mateos, Leire Burgos, Bruno Paiva, Jeroen te Marvelde, Vincent H. J. van der Velden, Carlos Aguilar, Abelardo Bárez, Aranzazú García-Mateo, Jorge Labrador, Pilar Leoz, Carmen Aguilera-Sanz, Brian Durie, Jacques J. M. van Dongen, Angelo Maiolino, Elaine Sobral da Costa, Alberto Orfao
Published 2021-04-01

Clinical Challenges and Consequences of Measurable Residual Disease in Non-APL Acute Myeloid Leukemia

by Madlen Jentzsch, Sebastian Schwind, Enrica Bach, Sebastian Stasik, Christian Thiede, Uwe Platzbecker
Published 2019-10-01

Measurable Residual Disease Detected by Multiparameter Flow Cytometry and Sequencing Improves Prediction of Relapse and Survival in Acute Myeloid Leukemia

by Fu-Jia Liu, Wen-Yan Cheng, Xiao-Jing Lin, Shi-Yang Wang, Tian-Yi Jiang, Ting-Ting Ma, Yong-Mei Zhu, Yang Shen
Published 2021-05-01

SERS-Based Assessment of MRD in Acute Promyelocytic Leukemia?

by Cristina Turcas, Cristina Turcas, Vlad Moisoiu, Vlad Moisoiu, Andrei Stefancu, Ancuta Jurj, Stefania D. Iancu, Patric Teodorescu, Patric Teodorescu, Sergiu Pasca, Sergiu Pasca, Anca Bojan, Anca Bojan, Adrian Trifa, Sabina Iluta, Sabina Iluta, Alina-Andreea Zimta, Bobe Petrushev, Mihnea Zdrenghea, Mihnea Zdrenghea, Horia Bumbea, Daniel Coriu, Delia Dima, Nicolae Leopold, Ciprian Tomuleasa, Ciprian Tomuleasa, Ciprian Tomuleasa
Published 2020-06-01

Post-induction Measurable Residual Disease Using Multicolor Flow Cytometry Is Strongly Predictive of Inferior Clinical Outcome in the Real-Life Management of Childhood T-Cell Acute...

by Prashant R. Tembhare, Gaurav Narula, Twinkle Khanka, Sitaram Ghogale, Gaurav Chatterjee, Nikhil V. Patkar, Maya Prasad, Yajamanam Badrinath, Nilesh Deshpande, Pratyusha Gudapati, Shefali Verma, Mahima Sanyal, Florence Kunjachan, Gunit Mangang, Sumeet Gujral, Shripad Banavali, Papagudi G. Subramanian
Published 2020-04-01

Myelodysplastic syndromes: Biological and therapeutic consequences of the evolving molecular aberrations landscape

by Sebastian Schwind, Madlen Jentzsch, Anne Sophie Kubasch, Klaus H. Metzeler, Uwe Platzbecker
Published 2021-11-01

Measurable Residual Disease-Guided Treatment to Prevent Relapse in Acute Myeloid Leukemia and Myelodysplastic Syndrome

by Jonathan Pan, Daniel Altman, Lindsay Wilde
Published 2020-10-01

Utility of Immunophenotypic Measurable Residual Disease in Adult Acute Myeloid Leukemia—Real-World Context

by Nikhil Patkar, Chinmayee Kakirde, Prasanna Bhanshe, Swapnali Joshi, Shruti Chaudhary, Yajamanam Badrinath, Sitaram Ghoghale, Nilesh Deshpande, Shraddha Kadechkar, Gaurav Chatterjee, Sadhana Kannan, Dhanalaxmi Shetty, Anant Gokarn, Sachin Punatkar, Avinash Bonda, Lingaraj Nayak, Hasmukh Jain, Bhausaheb Bagal, Hari Menon, Manju Sengar, Syed Hasan Khizer, Navin Khattry, Prashant Tembhare, Sumeet Gujral, Papagudi Subramanian
Published 2019-06-01

Evaluating Blinatumomab for the Treatment of Relapsed/Refractory ALL: Design, Development, and Place in Therapy

by Sigmund AM, Sahasrabudhe KD, Bhatnagar B
Published 2020-11-01

Haploidentical donor is preferred over matched sibling donor for pre-transplantation MRD positive ALL: a phase 3 genetically randomized study

by Ying-Jun Chang, Yu Wang, Lan-Ping Xu, Xiao-Hui Zhang, Huan Chen, Yu-Hong Chen, Feng-Rong Wang, Wei-Han, Yu-Qian Sun, Chen-Hua Yan, Fei-Fei Tang, Xiao-Dong Mo, Yan-Rong Liu, Kai-Yan Liu, Xiao-Jun Huang
Published 2020-03-01

Unsupervised Flow Cytometry Analysis Allows for an Accurate Identification of Minimal Residual Disease Assessment in Acute Myeloid Leukemia

by Jean Philippe Vial, Nicolas Lechevalier, Francis Lacombe, Pierre-Yves Dumas, Audrey Bidet, Thibaut Leguay, François Vergez, Arnaud Pigneux, Marie C. Béné
Published 2021-02-01

Analytical evaluation of the clonoSEQ Assay for establishing measurable (minimal) residual disease in acute lymphoblastic leukemia, chronic lymphocytic leukemia, and multiple myelo...

by Travers Ching, Megan E. Duncan, Tera Newman-Eerkes, Mollie M. E. McWhorter, Jeffrey M. Tracy, Michelle S. Steen, Ryan P. Brown, Srivatsa Venkatasubbarao, Nicholas K. Akers, Marissa Vignali, Martin E. Moorhead, Drew Watson, Ryan O. Emerson, Tobias P. Mann, B. Melina Cimler, Pamela L. Swatkowski, Ilan R. Kirsch, Charles Sang, Harlan S. Robins, Bryan Howie, Anna Sherwood
Published 2020-06-01

Measurable residual disease at myeloablative allogeneic transplantation in adults with acute lymphoblastic leukemia: a retrospective registry study on 2780 patients from the acute...

by Jiří Pavlů, Myriam Labopin, Riitta Niittyvuopio, Gerard Socié, Ibrahim Yakoub-Agha, Depei Wu, Peter Remenyi, Jakob Passweg, Dietrich W. Beelen, Mahmoud Aljurf, Nicolaus Kröger, Hélène Labussière-Wallet, Zinaida Perić, Sebastian Giebel, Arnon Nagler, Mohamad Mohty
Published 2019-10-01

Different Effects of Pre-transplantation Measurable Residual Disease on Outcomes According to Transplant Modality in Patients With Philadelphia Chromosome Positive ALL

by Si-Qi Li, Qiao-Zhen Fan, Lan-Ping Xu, Yu Wang, Xiao-Hui Zhang, Huan Chen, Yu-Hong Chen, Feng-Rong Wang, Wei Han, Yu-Qian Sun, Chen-Hua Yan, Fei-Fei Tang, Yan-Rong Liu, Xiao-Dong Mo, Xin-Yu Wang, Kai-Yan Liu, Xiao-Jun Huang, Xiao-Jun Huang, Ying-Jun Chang
Published 2020-03-01

Molecular and cellular markers for measurable residual disease in acute lymphoblastic leukemia

by Gerardo Juárez-Avendaño, Nereida Méndez-Ramírez, Nuria C. Luna-Silva, David Gómez-Almaguer, Rosana Pelayo, Juan C. Balandrán
Published 2021-07-01

Highly Sensitive and Accurate Assessment of Minimal Residual Disease in Chronic Lymphocytic Leukemia Using the Novel CD160-ROR1 Assay

by Timothy W. Farren, Timothy W. Farren, Kaushik S. Sadanand, Samir G. Agrawal, Samir G. Agrawal
Published 2020-12-01